Comera Life Sciences Holdings, Inc.

OTCPK:CMRA Stock Report

Market Cap: US$9.2k

Comera Life Sciences Holdings Valuation

Is CMRA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of CMRA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate CMRA's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate CMRA's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CMRA?

Key metric: As CMRA is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for CMRA. This is calculated by dividing CMRA's market cap by their current revenue.
What is CMRA's PS Ratio?
PS Ratio0.009x
SalesUS$1.00m
Market CapUS$9.22k

Price to Sales Ratio vs Peers

How does CMRA's PS Ratio compare to its peers?

The above table shows the PS ratio for CMRA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average3.5x
ARDS Aridis Pharmaceuticals
0.000002xn/aUS$53.0
GNCA.Q Genocea Biosciences
0.003xn/aUS$5.9k
VBIV.Q VBI Vaccines
0.002xn/aUS$14.3k
ADTX Aditxt
14xn/aUS$2.8m
CMRA Comera Life Sciences Holdings
0.009xn/aUS$9.2k

Price-To-Sales vs Peers: CMRA is good value based on its Price-To-Sales Ratio (0x) compared to the peer average (4.7x).

Price to Sales Ratio vs Industry

How does CMRA's PS Ratio compare vs other companies in the US Biotechs Industry?

129 CompaniesPrice / SalesEstimated GrowthMarket Cap
Industry Avg.9.7x21.3%
CMRA Comera Life Sciences Holdings
 0.009xn/aUS$9.22k
GILD Gilead Sciences
4x2.4%US$111.86b
BIIB Biogen
2.4x1.3%US$23.03b
CMRA 0.0xIndustry Avg. 9.7xNo. of Companies129PS01632486480+
129 CompaniesEstimated GrowthMarket Cap
Industry Avg.9.7x28.4%
CMRA Comera Life Sciences Holdings
 0.009xn/aUS$9.22k
No more companies

Price-To-Sales vs Industry: CMRA is good value based on its Price-To-Sales Ratio (0x) compared to the US Biotechs industry average (9.7x).

Price to Sales Ratio vs Fair Ratio

What is CMRA's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CMRA PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.009x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate CMRA's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Spectrum Pharmaceuticals

US$209.9m

Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products.

SPPI

US$1.03

7D

5.3%

1Y

17.0%

IQVIA Holdings

US$35.9b

Engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.

IQV

US$201.82

7D

4.7%

1Y

-4.8%

Teva Pharmaceutical Industries

US$19.4b

Develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally.

TEVA

US$17.12

7D

4.2%

1Y

79.3%